Παρασκευή 29 Νοεμβρίου 2013

Pedestrian Injuries on the Rise for Teens on Cell Phones

Pedestrian Injuries on the Rise for Teens on Cell Phones

Neil Osterweil
November 26, 2013
BOSTON — There has been a recent upswing in injuries in older teens, probably because they are paying more attention to their cell phones than to where they are going.
That is the contention of investigators from Safe Kids Worldwide, a global nongovernmental organization dedicated to preventing injuries, the leading cause of death in children in the United States.
A Safe Kids recent study showed that distracted walking is as serious a public safety issue as distracted driving, Kristin Rosenthal, program manager for pedestrian and bike safety at that organization, told Medscape Medical News.
"We did observations at middle schools and high schools of kids crossing the street, and we observed 34,000 kids walking. We found that 1 in 5 high schoolers and 1 in 8 middle schoolers were distracted by some kind of electronic device while crossing the street," she said.
The most frequent distracted behaviors were texting (39% of observations) and the use of headphones (39%). Girls were more frequently seen walking while distracted than boys, but the pedestrian death rate for boys is 1.8 times higher than for girls.
Rosenthal and her colleague at Safe Kids Worldwide, Angela Mickalide, PhD, examined 1995 to 2010 data on pedestrian deaths from the National Highway Traffic Safety Administration Fatality Analysis Reporting Systems database and on nonfatal injuries from the General Estimates System.
The study results were presented here at the American Public Health Association 141st Annual Meeting.
 
We've had a pretty big drop in the number of little kids we see and a pickup in the teenagers.
 
From 1995 to 2009, there was a 53% decline in the pedestrian death rate and a 44% decline in the injury rate. However, in 2009 and 2010, there was an uptick in deaths and in injuries.
"Interestingly, the most at-risk age group has shifted since 1995 when 5 to 9 year olds sustained the most injuries, to today when teens are at greatest risk. The death rate among older teens is now twice that of younger children," the investigators report.
They saw a 25% increase in injuries in 16 to 19 year olds over the previous 5 years, and 14 to 19 year olds currently account for half of all child pedestrian injuries.
Table. Change in Injury Rates From 2001–2005 to 2006–2010
Age Group (Years)Percent Change
1–4–31
5–9–34
10–15–16
16–19+25

The investigators speculate that "the rapid increase in the use of cell phone and other technologies while walking in this age group may be responsible for this increase."
Member institutions of the Safe Kids coalition interviewed 2441 preteens and teens about their walking behaviors. In all, 49% said they used a cell phone while walking, 40% said they used an mp3 player, and 6% said they used another mobile device, such as a handheld game console.
But as is typical for adolescents, 78% said that the group most at risk for pedestrian injuries was either younger than they were (50%) or older than they were (28%). Only 22% said their own age group was the most at risk.
The investigators recommend that parents and guardians talk to teens about the dangers of distracted walking, and advise them to stop using mobile devices while crossing the street. They recommend starting the message when the child gets his or her first mobile device, modeling good street-crossing behavior, and urging their children to speak up when they see someone walking distractedly.
David Mooney, MD, director of the trauma program at Boston Children's Hospital, who was not involved in this study, told Medscape Medical News that he frequently sees kids who have been injured in pedestrian accidents due to inattention.
"What we see kind of mirrors what the folks from Safe Kids saw. We've had a pretty big drop in the number of little kids we see and a pickup in the teenagers," he said.
Dr. Mooney reported that he has treated patients who were injured after walking into the road and getting hit by a car, although patients are often reluctant to admit that they haven't been paying attention, whether because of a mobile device or other distraction. "I certainly have seen cases where people got hit because they were on the phone," he said.
Dr. Mooney said he has also treated patients who were injured walking into poles on sidewalks when their attention was elsewhere.
He noted that pedestrian injuries in kids are particularly problematic in areas where there is no sidewalk and children are forced to walk in the street.
"If you're in a street, or crossing a street, it's really a bad idea to not be paying attention," Dr. Mooney said.
Safe Kids Worldwide is supported by private donations and by corporate partners Johnson & Johnson, Bell Sports, General Motors, and FedEx. Ms. Rosenthal and Dr. Mooney have disclosed no relevant financial relationships, although Ms. Rosenthal is an employee of Safe Kids.
American Public Health Association (APHA) 141st Annual Meeting: Abstract 287877. Presented November 3, 2013.

Τρίτη 19 Νοεμβρίου 2013

Fine-Tuning the Ketogenic Diet Helpful

Fine-Tuning the Ketogenic Diet Helpful

Megan Brooks
November 06, 2013
AUSTIN, Texas — Fine-tuning the ketogenic diet can have a modest effect on seizure control in children with refractory epilepsy, a retrospective study suggests.
The researchers found that adjusting diet and changing medications had similar benefits and were helpful in meeting seizure control expectations in about 1 in 5 children.
Jessica Selter, a medical student at Johns Hopkins University School of Medicine in Baltimore, Maryland, presented the findings here at the Child Neurology Society (CNS) 2013 Annual Meeting.
No Single "Stand Out" Dietary Change
The high-fat, low-carbohydrate ketogenic diet has "repeatedly" been shown to be effective in children with refractory epilepsy, "but some children don't have a complete response," Selter noted in an interview with Medscape Medical News.
"In this case, clinicians and dietitians will often try to make fine-tuning changes to the diet through dietary or medication adjustments to try to impact future control. But there really is a lack of evidence on the impact of those fine-tuning changes on future seizure control," Selter explained.
"We tried to characterize the fine-tuning changes that are made and determine their efficacy and in particular try to see if there was one that really stood out as most effective," she said.
The researchers reviewed the charts of 200 children who started the ketogenic diet at Johns Hopkins Hospital between October 2007 and June 2013. In most of these children (n = 156 [78%]), at least 1 change (intervention) was attempted. The chart review showed a total of 391 distinct and occasionally concurrent interventions, of which 256 were made specifically for seizure control.
"We found that there was an 18% chance that any change would lead to a greater than 50% seizure reduction but there was a 3% chance that a change would lead to resulting seizure freedom," Selter said. It's important to note that the likelihood of success did not decrease with each subsequent intervention, she noted.
No single dietary change stood out as the most effective, but calorie changes to the diet might be the least helpful, the researchers report. Increasing the fat to carbohydrate ratio and adding carnitine and medium-chain triglyceride (MCT) oil were similar and were more likely to help than was reducing calories, they say.
Predictors of a dietary change leading to seizure improvement were younger age (3.6 vs 5.1 years; P = .02), young age at seizure onset (1.2 vs 2 years; P = .049), and lower seizure frequency at baseline (230 vs 572 seizures per month; P = .003).
There was a trend for medication adjustment to be slightly more likely than dietary modification to lead to greater than 50% seizure reduction (24% vs 15%; P = .08). Medication adjustment is a "viable option and might make more of a difference as an add-on" to the ketogenic diet, the researchers conclude.
Overall, this study shows that fine-tuning the ketogenic diet can have a "modest impact on seizure control," Selter and colleagues conclude.
"While it makes sense to try to fine-tune the diet," Selter said, "it's important for clinicians and dietitians to talk with patients and parents and be realistic that there really isn't a very high likelihood that these fine-tuning changes can lead to seizure freedom. It's important to work with patients and their families to make these changes."
Benefits Beyond Seizure Control
Reached for comment, Elizabeth Donner, MD, pediatric neurologist at the Hospital for Sick Children, and associate professor, University of Toronto, Ontario, Canada, said, "It's important to note that this abstract reports the results of fine-tuning the diet on seizure outcome" only.
"In our experience, fine-tuning the diet allows for improvements not only in seizure control, but also in tolerability of the diet and palatability of the diet," she toldMedscape Medical News. "More kids are able to take the diet if you are willing to make fine adjustments. Therefore, an important message is that adjustments can be made to the diet not just for seizure control but to assist children and families who are having difficulty sticking with the diet."
Dr. Donner also noted that the ketogenic diet is rigid and needs to be prescribed by an experienced medical team. "It is not something that can be implemented at home," she said, "but it actually can be flexible and there is some flexibility in how we use the diet. And that means we should consider using it in any kid who has drug-resistant seizures and are not surgical candidates. It needs to be on your list of options."
The ketogenic diet is also labor intensive and requires a lot of follow-up, she noted. "We see these kids before starting the diet to see if they are good candidates and once started on the diet, we see them back typically at 1 month, 2 months, and 3 months, then every 3 months and then eventually every 6 months," Dr. Donner said.
"If the family is coming from far away, then we have a conversation about whether it is feasible for them to come back for all those follow-up appointments. We try to do some of them by telemedicine. And between those follow-up appointments, families are typically in touch with our RN, our nurse practitioner, and our dietitian, making changes and talking about things between appointments," she said.
The authors and Dr. Donner have disclosed no relevant financial relationships.
Child Neurology Society (CNS) 2013 Annual Meeting. Abstract #170. Presented October 31, 2013.

Choosing Wisely in Pediatric Hospital Medicine

Results

The initial list of 20 candidate tests and treatments as well as the refined list of 11 recommendations can be found as electronic supplements to this publication (see Supporting Table 1 and Supporting Table 2 in the online version of this article). The format and language of the list of 11 recommendations were chosen to mesh with that typically used in the ABIM-F Choosing Wisely campaign. During the Delphi panel, there was strong group consensus about combining items 1 and 2 (chest radiographs in asthma and bronchiolitis) into a single recommendation.
The top 5 recommendations based on the result of the second round of Delphi scoring are shown in and described below along with a detailed evidence summary.

Table 1.  Top Five Pediatric Hospital Medicine Recommendations

Do not order chest radiographs in children with asthma or bronchiolitis.
Do not use bronchodilators in children with bronchiolitis.
Do not use systemic corticosteroids in children under 2 years of age with a lower respiratory tract infection.
Do not treat gastroesophageal reflux in infants routinely with acid suppression therapy.
Do not use continuous pulse oximetry routinely in children with acute respiratory illness unless they are on supplemental oxygen.
Do not order chest radiographs in children with asthma or bronchiolitis.
The National Heart and Lung Institute's guidelines for the management of asthma, published in 1987, recommend against routinely obtaining chest radiographs in patients with asthma or asthma exacerbations.[8] Supporting this recommendation are several studies that show a low overall yield when obtaining chest radiographs for wheezing patients.[9-11] Most relevant, studies that evaluated the clinical utility of radiographs in patients with asthma have demonstrated that they influence clinical management in less than 2% of cases.[12] A quality improvement project aimed at decreasing the rate of chest radiographs obtained in patients with asthma demonstrated that close to 60% of patients admitted to the hospital had chest radiographs performed, and that significant overall reductions can be achieved (45.3%–28.9%, P = 0.0005) without impacting clinical outcomes negatively.[13]
Similarly, the Subcommittee on Diagnosis and Management of Bronchiolitis of the American Academy of Pediatrics recommends against routinely obtaining radiographs during the evaluation for bronchiolitis.[14] Studies assessing the utility of chest x-rays in these children demonstrate an even lower incidence of abnormalities (0.75%) and indicate that, despite this low incidence, physicians are more likely to treat with antibiotics when radiographs are obtained.[15] There is also evidence that chest radiographs in patients with bronchiolitis are not useful in predicting severity of illness.[16] Furthermore, cost-effective analyses have demonstrated that omitting chest radiographs in bronchiolitis is actually cost-effective, without compromising diagnostic accuracy.[17] In a recently published national benchmarking inpatient collaborative, Ralston et al. demonstrated that the majority of patients admitted to the hospital with bronchiolitis have chest radiographs performed at a rate of 64% (interquartile range [IQR], 54%–81%).[18]
In both bronchiolitis and asthma, the elimination of unnecessary radiographs has the potential to decrease costs, reduce radiation exposure, and minimize the overuse of antibiotics that often occurs secondary to false positive results.
Do not use bronchodilators in children with bronchiolitis.
Ralston showed that 70% (IQR, 59%–83%) of admitted bronchiolitis patients received bronchodilators with an average of 7.9 doses per patient (IQR, 4.6–9.8). National guidelines for bronchiolitis suggest a very limited role of bronchodilators in patients with bronchiolitis.[14] The first meta-analyses of studies related to the question of β-agonist efficacy in bronchiolitis were published in the late 1990s, revealing minimal or no treatment effects.[19, 20] Since then, further research has solidified these findings, and fairly definitive statements can be made based on a recent comprehensive meta-analysis.[21] The pooled data do not show any effect on hospitalization rates, hospital length of stay, or other inpatient outcomes in bronchiolitis. They do show a small change in clinical scores documented in the outpatient setting, though these scores have not correlated with any detectable difference in outcomes. Routine use of β-agonists in the inpatient setting has no proven benefit, and given the large amount of consistent data, there is no compelling reason for further study of this therapy in the inpatient setting.
Epinephrine, a combined β- and α-agonist, has been extensively evaluated in bronchiolitis as well. Like albuterol, epinephrine has been reported to have no effect on hospital length of stay in bronchiolitis.[22] The issue of admission rates after epinephrine is complicated by 1 very large study that combined epinephrine with dexamethasone and reported a decreased admission rate, though only at 7 days after therapy; however, this effect was nullified after adjustment for multiple comparisons.[23] When the end point is improvement of respiratory scores, epinephrine may perform better than albuterol in studies where they are directly compared; however, there is no evidence that repeated usage of epinephrine has any impact on any clinical outcome for inpatients.[24, 25]
Do not use systemic corticosteroids in children under 2 years of age with a lower respiratory tract infection
In their summary of evidence, the Subcommittee on Diagnosis and Management of Bronchiolitis of the American Academy of Pediatrics recommends against routinely using systemic corticosteroids for infants with bronchiolitis.[14] The previously reference bronchiolitis benchmarking study demonstrated that admitted patients received steroids at a rate of 21% (IQR, 14%–26%). The poor efficacy of corticosteroids in children with bronchiolitis under 2 years of age is well demonstrated in the literature. A large, blinded, randomized, controlled study compared systemic oral corticosteroids to placebo in hospitalized children 10 months to 6 years of age with viral wheezing.[26] This study showed no benefit of corticosteroids over placebo in length of stay or parental report of symptoms 1 week later. In the study, a subanalysis of children with eczema and family history of asthma also demonstrated no benefit of systemic corticosteroids. Large systematic reviews further argue that there is no effect of corticosteroids on the likelihood of admission or length of stay in infants with bronchiolitis.[27, 28] One 4-armed prospective study of children 6 weeks to 12 months of age found no efficacy of dexamethasone over placebo.[23] There was modest benefit of dexamethasone in conjunction with racemic epinephrine; however, this benefit disappeared after adjustment for multiple comparisons. Three smaller studies showing benefit of systemic corticosteroids, however, were highly problematic. They have included older children, were retrospective, or demonstrated inconsistent results.[29, 30] A smaller study showed benefit for children over 2 years of age, but none for children under 2 years of age.[31] Premature infants are at increased risk of asthma, which typically responds well to corticosteroids as these children get older. However, a retrospective study of premature infants under 2 years of age with bronchiolitis demonstrated no association between corticosteroid use and length of stay, even in the subset of premature infants responding to albuterol.[32]
Systemic corticosteroid use in children is not harmless. Children under 2 years of age are especially vulnerable to the decreased growth velocity seen as a side effect of systemic corticosteroids.[33] Corticosteroids may also negatively impact the course of infectious illness. For instance, in children hospitalized with pneumonia but not receiving β-agonists (ie, patients who are unlikely to have asthma), length of stay is prolonged and readmission is higher in those who receive corticosteroids.[34]
Do not treat gastroesophageal reflux in infants routinely with acid suppression therapy.
From 2000 to 2005, the incidence of infants diagnosed with gastroeshopaheal reflux (GER) tripled (3.4%–12.3%), and the use of proton pump inhibitors (PPIs) doubled (31.5%–62.6%).[35] Patients diagnosed with GER and treated with antireflux medication incurred 1.8 times higher healthcare costs in 1 study compared to healthy controls.[36] Though common, the use of acid suppressive medications in infants lacks evidence for efficacy in the majority of the clinical scenarios in which they are prescribed.[37, 38] PPIs have failed to outperform placebo for typical infant reflux, which is generally developmental and not pathologic.[39, 40] Furthermore, prompted by findings in adults, multiple pediatric investigators have now catalogued the potential risks associated with acid blockade in children in multiple clinical settings. Specifically, increased risk of pneumonia has been documented in inpatients and outpatients, and increased risk of necrotizing enterocolitis and other serious infections have been documented in intensive care unit settings.[41] In the absence of data supporting efficacy and given the emerging data on risk, empiric acid suppression in infants with reflux is wasteful and potentially harmful.
Do not use continuous pulse oximetry routinely in children with acute respiratory illness unless they are on supplemental oxygen.
Pulse oximetry use has become widespread in the management of infants with bronchiolitis and likely accounts for the dramatic increase in bronchiolitis hospitalization rates in recent years.[14, 42-47] Despite this increase in hospitalization rate, there was no change in mortality from bronchiolitis between 1979 and 1997.[48] The continuous monitoring of oxygen saturations in hospitalized infants with bronchiolitis may lead to overdiagnosis of hypoxemia and subsequent oxygen use that is of no apparent benefit to the child. Schroeder et al. demonstrated that 26% of a sample of infants hospitalized with bronchiolitis had a prolonged length of stay because of a perceived need for oxygen based on pulse oximetry readings.[43] Unger and Cunningham showed that the need for oxygen was the final determinant of length of stay in 58% of cases, and Cunningham and Murray suggested that using an oxygen saturation cutoff of 94% instead of 90% might increase the length of stay by ~22 hours.[44, 49]
It has been previously shown that hypoxia is normative in infants. Healthy infants experience multiple episodes of SpO2 ≤90% while sleeping.[50] This finding strengthens the notion that detection of low saturations in infants convalescing from bronchiolitis may simply reflect overdiagnosis. Among children with chronic severe asthma, who presumably have experienced episodes of hypoxia throughout childhood, there is no difference in school performance compared to healthy controls.[51]
The practice parameter on bronchiolitis from the American Academy of Pediatrics states: "as the child's clinical course improves, continuous measurement of SpO2 is not routinely needed," which is a recommendation based on expert consensus.[14] There is at least one ongoing randomized trial comparing the use of continuous versus intermittent pulse oximetry in hospitalized infants with bronchiolitis who are weaned off oxygen (clinicaltrials.gov NCT01014910). An interim analysis of this trial revealed no safety concerns with intermittent pulse oximetry over continuous monitoring.[52] Given the substantial risks and resources associated with prolonged bronchiolitis hospitalizations, a reduction in pulse oximetry use has great potential to reduce costs and improve overall care.

Discussion

Berwick and Hackbarth define overtreatment as: "waste that comes from subjecting patients to care that, according to sound science and the patients' own preferences, cannot possibly help them—care rooted in outmoded habits, supply-driven behaviors, and ignoring science."[1] With this project, we tried to capture common clinical sources of waste in the inpatient pediatric setting. This is an inherently difficult project because of the absence of solid evidence to inform every decision point in medicine. Although there is always room for improvement in our evidence base, our group intentionally gravitated to areas where the evidence was robust.
The primary strength of this work is the use of the RAND/UCLA appropriateness method or modified Delphi method. Several publications have validated this methodology as a sound strategy to assess quality indicators and issues related to overuse.[7, 53] To our knowledge, we are the first group to report the use of this methodology to develop a list such as the list reported here.
There were some challenges inherent to this project that can be considered limitations of the work. One perceived limitation of our list is the heavy concentration on respiratory diagnoses, especially bronchiolitis and asthma. We do not feel this is a genuine limitation, as the recommendations were partly driven by volume and costs as assessed by the KID database. Among the top 10 acute inpatient diagnoses in pediatrics, respiratory diagnoses are the most common, including bronchiolitis, pneumonia, and asthma. Pneumonia or bronchiolitis has been the most common medical diagnosis in inpatient pediatrics for the past decade, and both are always in the top 10 for costs as well.[54] Thus, the impact of decreasing overuse for these conditions will be highly significant from a simple volume standpoint.
The primary limitation of this work is the lack of implementation strategies. Although the Choosing Wisely campaign has plans for dissemination of the lists, compliance with the recommendations may be suboptimal. Although the development process followed an accepted methodology, shortcomings include the lack of wide, local, multidisciplinary (including parents or caretakers) consultation. Other barriers to compliance with these recommendations exist. Despite evidence that bronchiolitis is a benign self-limited disease that does not respond to bronchodilators and steroids, the drive to identify and correct all abnormalities, such as wheezing or low oxygen saturation in a nontoxic infant with bronchiolitis, seems to trump the obligation to do no harm in daily practice.[55] This behavior may result from pressure by patients, families, nurses, or peers and is deeply embedded in our medical culture, where action is preferred to inaction without full knowledge or consideration of risks. Doctors and nurses have become attached to the pulse oximeter, believing somehow that the number displayed is less subjective and holds more predictive value than careful evaluation of the patient's respiratory status. Other pressures, such as direct to consumer marketing have made acid reflux a household term that is easily treated with over-the-counter medications. Considerations of the care continuum will also serve as barriers. Chest x-rays, for example, are frequently obtained prior to admission to the hospital before the hospitalist is involved.
To overcome these limitations, the study of individual and organizational adoption of innovation might be relevant. Though it is complex and often more descriptive than proscriptive, a few salient features have emerged. Champions and opinion leaders make a difference, local culture is dominant, social networking is important, simple innovations that can be trialed on a small scale are adaptable by the user and have observable benefits, are more likely to be adopted.[56] Fortunately, the top 5 list meets many of these criteria, but also faces the daunting challenges of inertia, lack of financial incentive, inability to break with old habits, and fear of lawsuits and perceived patient/parent dissatisfaction. Ongoing evaluation, feedback, and audit will be necessary to detect and sustain change.

Conclusion



We have identified 5 tests or therapies overused in inpatient general pediatrics. One goal of the Choosing Wisely campaign is to begin to change social norms related to physician behavior. We hope by asking clinicians to consider doing less for common conditions in inpatient pediatrics, that they will increasingly consider the known and unanticipated risks of any medical interventions they choose to use. Finally, we would like to encourage all pediatricians to embrace the idea of good stewardship and join us in prioritizing and addressing waste and overuse as important patient safety issues as well as threats to the sustainability of our healthcare system.

Τρίτη 12 Νοεμβρίου 2013

Choosing Wisely in Pediatric Hospital Medicine

ACIP Approves 2014 Child/Adolescent Immunization Schedule

ACIP Approves 2014 Child/Adolescent Immunization Schedule

Troy Brown, RN
October 23, 2013
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) unanimously approved the 2014 Child/Adolescent Immunization Schedule today, which includes some changes to the current schedule. The committee works closely with the American Academy of Pediatrics, American Academy of Family Physicians, and American Congress of Obstetricians and Gynecologists to develop the guidelines, which are updated annually.
The 2014 guidelines include the following changes:
  • Pneumococcal vaccine: A section in the footnotes separates various risk groups by age (ages 24 - 71 months and 6 - 18 years) and provides recommendations regarding 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. There are separate guidelines for children aged 6 to 18 years who are immunocompromised and for those with chronic conditions who are not immunocompromised. A vaccine catch-up table is also included.
  • Hepatitis A vaccine: The guidelines now include individuals who travel to or work in countries with high or intermediate endemicity of infection, men who have sex with men, those who use injection or noninjection illicit drugs, those who work with hepatitis A virus (HAV)-infected primates or with HAV in a research laboratory, those with clotting-factor disorders, and those with chronic liver disease.
  • Human papillomavirus vaccine: The guidelines have been changed to add that the third dose should be administered "at least 12 weeks after the second dose AND at least 24 weeks after the first dose," according to information provided at the meeting.
  • Meningococcal vaccines: The guidelines now recommend that the MenACWY-CRM (Menveo, Novartis Vaccines) vaccine may be given as early as 2 months of age for those with high risk for meningococcal disease. The guidelines include detailed instructions for use of the vaccines, as well as catch-up recommendations.
  • Tdap vaccine: Those aged 11 years and older who have received no Tdap vaccine should have a Tdap followed by tetanus and diphtheria toxoids booster doses every 10 years after that. The committee does not recommend repeat doses of Tdap, except for pregnant adolescents, during each pregnancy. The guidelines also advise that in adolescents (aged 11 - 18 years) who inadvertently receive a pediatric DTaP, that dose should be considered the adolescent Tdap booster.
Sometimes the language in the child and adolescent guidelines overlaps with that in the adult guidelines and should be clearer, said voting member and committee chair Jonathan L. Temte, MD, PhD, a professor of family medicine at the University of Wisconsin School of Medicine and Public Health in Madison. Regarding the pneumococcal vaccines "for the asplenics and the sickle cell, it might be worthwhile to provide guidance as to what happens after they turn 19," Dr. Temte noted.
The ACIP and CDC will revise these guidelines based on today's meeting and will submit finalized guidelines to the American Academy of Pediatrics, American Academy of Family Physicians, and American Congress of Obstetricians and Gynecologists by January 1, 2014. The CDC will publish the guidelines on its Web site in January 2014, and Pediatrics and American Family Physician will publish them in February 2014.
One of the voting members reported that her institution receives grant money from pharmaceutical companies for research. The other voting members have disclosed no relevant financial relationships.

Narrow-Spectrum Antibiotics Effective for Pediatric Pneumonia

Narrow-Spectrum Antibiotics Effective for Pediatric Pneumonia

Joe Barber Jr, PhD
October 29, 2013
Narrow-spectrum antibiotics have similar efficacy and cost-effectiveness as broad-spectrum antibiotics in the treatment of pediatric community-acquired pneumonia (CAP), according to the findings of a retrospective study.
Derek J Williams, MD, MPH, from Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues published their findings online October 28 inPediatrics.
"The 2011 Pediatric Infectious Diseases Society/Infectious Diseases Society of America...guideline for the management of children with [CAP] recommends narrow-spectrum antimicrobial therapy for most hospitalized children," the authors write. "Nevertheless, few studies have directly compared the effectiveness of narrow-spectrum agents to the broader spectrum third-generation cephalosporins commonly used among hospitalized children with CAP."
Therefore, the researchers used the Pediatric Health Information System database to assess the hospital length of stay (LOS) and associated healthcare costs of children aged 6 months to 18 years who were diagnosed with pneumonia between July 2005 and June 2011 and treated with either narrow-spectrum or broad-spectrum antibiotics. The authors excluded children with potentially severe pneumonia, those at risk for healthcare-associated infections, and those with mild disease requiring less than 2 days of hospitalization.
Narrow-spectrum therapy consisted of the exclusive use of penicillin or ampicillin, whereas broad-spectrum treatment was defined as the exclusive use of parenteral ceftriaxone or cefotaxime.
The median LOS for the entire study population (n = 15,564) was 3 days (interquartile range, 3 - 4 days), and LOS was not significantly different between the narrow-spectrum and broad-spectrum treatment groups (adjusted difference [aD], 0.12 days; P = .11), after adjustments for covariates including age, sex, and ethnicity.
Similarly, the investigators found no differences in the proportion of children requiring intensive care unit admission in the first 2 days of hospitalization (adjusted odds ratio [aOR], 0.85; 95% CI, 0.25 - 2.73) or hospital readmission within 14 days (aOR, 0.85; 95% CI, 0.45 - 1.63) were noted between the groups.
Narrow-spectrum treatment was also linked to a similar cost of hospitalization (aD, −$14.4; 95% CI, −$177.1 to $148.3) and cost per episode of illness (aD, −$18.6; 95% CI, −$194 to $156.9) as broad-spectrum therapy.
The researchers note that the limitations of the study were mostly related to its retrospective nature, including potential confounding by indication, the absence of etiologic and other clinical data, and a relative lack of objective outcome measures.
"Clinical outcomes and costs for children hospitalized with CAP are not different when empirical treatment is with narrow-spectrum compared with broad-spectrum therapy," the authors write. "Programs promoting guideline implementation and targeting judicious antibiotic selection for CAP are needed to optimize management of childhood CAP in the United States."
The authors have disclosed no relevant financial relationships.
Pediatrics. Published online October 28, 2013. Abstract